TAC Health Card | Alzheimer’s disease / neuroinflammation target validation
T layer — Mechanistic evidence
Status: STRONG / EMERGING
TREM2 is a microglial receptor involved in innate immune signaling, phagocytic activity, lipid sensing, and neuroinflammatory response.
Mechanistic studies support a role for TREM2 in regulating microglial state transitions relevant to neurodegeneration.
The biological rationale is increasingly coherent, though still evolving in disease-context detail.
Φ layer — Genetic evidence
Status: STRONG
Human genetics strongly support the relevance of TREM2 in Alzheimer’s disease risk.
Rare coding variants in TREM2 are associated with materially increased disease susceptibility, making it one of the clearest microglial genetic signals in neurodegeneration.
Genetic evidence supports target prioritization at the pathway and target level.
Σ layer — Clinical evidence
Status: PARTIAL / UNRESOLVED
Clinical translation remains incomplete.
While TREM2-directed programs have attracted major interest, the field has not yet produced definitive patient-level efficacy data establishing mature translational closure.
Current evidence supports continued development, but not full decision certainty.
TREM2 represents a high-interest frontier target with strong genetic support and increasingly compelling mechanistic logic, but incomplete clinical validation.
Cross-layer evidence alignment indicates significant translational promise while preserving uncertainty at the intervention layer.
This is a classic “scientifically prioritized, clinically unresolved” topology.
Why this case matters
TREM2 is important because it shows how TAC Topology distinguishes between failed legacy hypotheses and emerging next-generation neurodegeneration strategies.
Unlike BACE1, where clinical evidence closed negatively, TREM2 remains an open translational frontier.